RCS - PureTech Health PLC - PRTC's Seaport Adds Neuropsychiatry Veteran to BOD

Puretech HealthAnnouncement

Mon 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260427:nRSa9985Ba&default-theme=true

RNS Number : 9985B  PureTech Health PLC  27 April 2026

27 April 2026

PureTech Health plc

 

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies
Founder and CEO, Dr. Sharon Mates, to its Board of Directors

 

PureTech Health plc (https://puretechhealth.com/)  (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company
dedicated to giving life to science and transforming innovation into value,
notes that its Founded Entity, Seaport Therapeutics, today announced the
appointment of Dr. Sharon Mates to its Board of Directors.

 

Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of
Intra-Cellular Therapies, Inc. from inception of the company in June 2002
until its acquisition by Johnson & Johnson (J&J) in 2025 for
approximately $14.6 billion. She has decades of experience in neuropsychiatry,
guiding a company she founded through successful commercialization and a major
strategic transaction.

 

The full text of the announcement from Seaport is as follows:

 

Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon
Mates, to its Board of Directors

 

 Dr. Mates grew Intra-Cellular from discovery and early innovation through
commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson
& Johnson

 

Seaport Therapeutics (https://seaporttx.com/) ("Seaport" or the "Company"), a
clinical-stage therapeutics company that is inventing and developing
neuropsychiatric medicines, today announced the appointment of Dr. Sharon
Mates to its Board of Directors.

 

Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of
Intra-Cellular Therapies, Inc. from inception of the company in June 2002
until its acquisition by Johnson & Johnson (J&J) in 2025 for
approximately $14.6 billion. She has decades of experience in neuropsychiatry,
guiding a company she founded through successful commercialization and a major
strategic transaction.

 

"Sharon is an exceptional biotech entrepreneur and leader whom I have admired
for years. We are delighted to welcome her to our Board," said Daphne Zohar,
Founder and Chief Executive Officer of Seaport Therapeutics. "Her significant
experience, intellectual curiosity, deep industry relationships, and genuine
appreciation for our patient-centered approach will meaningfully support
Seaport's mission to develop life-changing treatments for patients with
depression, anxiety, and other neuropsychiatric disorders."

 

"I have followed Seaport's programs with great interest and believe Seaport is
positioned to have a significant impact in neuropsychiatry," said Dr. Sharon
Mates. "I look forward to working closely with Daphne as I have long respected
the vision and leadership she brings as a fellow founder and CEO whose work
has impacted patients. I'm also excited about collaborating with long-time
colleagues from the neuropsychiatry field including Steve Paul, Tony Loebel,
and other members of the team and Board to help guide Seaport's continued
growth and advance its mission to develop life-changing treatments for
patients."

 

Under Dr. Mates' leadership, Intra-Cellular Therapies developed medicines for
mental health disorders including bipolar disorder, depression, and
schizophrenia, and received U.S. Food and Drug Administration (FDA) approval
for its novel antipsychotic CAPLYTA®, which generated greater than $1.5
billion in sales prior to the company's acquisition by J&J, and continued
its commercial growth thereafter driven by expanded market reach and
additional FDA approvals.

 

"Sharon brings scientific and strategic depth in neuropsychiatry, including
completing the journey from complex neuroscience drug discovery to
real‑world medicines," said Steven Paul, M.D., Co-Founder and Board Chair of
Seaport Therapeutics. "Having witnessed Sharon's impact on CNS drug
development over many decades, it is a privilege to serve alongside her on the
Board as we extend that impact through our work at Seaport developing
important new medicines for patients with debilitating neuropsychiatric
disorders."

 

Dr. Mates brings board-level and governance experience, having served on
biotech and biopharmaceutical company boards, as well as several
not-for-profit boards. She currently serves on the boards of Medincell
(Euronext: MEDCL) and Benitec (Nasdaq: BNTC). Dr. Mates is presently forming a
new company in the areas of inflammation, metabolism, and other indications.
Earlier in her career, she was a research analyst, investment banker, and an
advisor to the life sciences industry. Dr. Mates received a B.S. from Ohio
State University, a Ph.D. from the University of Washington and completed her
postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical
School.

 

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage therapeutics company focused on
inventing and developing new medicines for patients with depression, anxiety,
and other debilitating neuropsychiatric disorders. Through its differentiated
approach, the Company identifies clinically validated mechanisms with
established efficacy and safety which had historically been limited by high
first-pass metabolism, low bioavailability, and/or side effects. Seaport
applies its proprietary Glyph(TM) platform to overcome those limitations and
invent innovative oral therapies. With an experienced team of industry
leaders, Seaport has a proven track record in neuropsychiatry drug discovery
and development and delivering successful business outcomes. Seaport aims to
develop novel, leading treatment options that will make a significant impact
for patients and their families. For more information, please
visit www.seaporttx.com (http://www.seaporttx.com/) .

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com or connect with us on
LinkedIn (https://www.linkedin.com/company/puretech-health/) and X (formerly
Twitter) @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to those related to Seaport's
development plans for its pipeline of neuropsychiatric therapeutics based on
the Glyph™ Platform, the potential of the Glyph platform, the broader
applicability of the platform, potential benefits to patients, and Seaport's
and our future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to known and
unknown risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially from current
expectations, including, but not limited to, those risks, uncertainties and
other important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2024, filed with
the SEC and in our other regulatory filings. These forward-looking statements
are based on assumptions regarding the present and future business strategies
of the Company and the environment in which it will operate in the future.
Each forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we disclaim
any obligation to update or revise these forward-looking statements, whether
as a result of new information, future events or otherwise.

 

Contact:

PureTech
Public Relations
publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations
IR@puretechhealth.com (mailto:IR@puretechhealth.com)

UK/EU Media
Ben Atwell, Rob Winder

+44 (0) 20 3727 1000
puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

US Media
Justin Chen
jchen@tenbridgecommunications.com (mailto:jchen@tenbridgecommunications.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAELXASKKEEA



            Copyright 2019 Regulatory News Service, all rights reserved